Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology.
Source: US Top News and Analysis
Related Posts
Offer ending soon: Earn a $250 Chase Freedom Unlimited welcome bonus
This simple cash back credit card has a $250 bonus and can be paired with…
Indian drugmaker Sun Pharma to buy U.S. firm Organon in $11.75 billion deal
To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co…
DOJ charges Southern Poverty Law Center with fraud over secret funding of extremist groups
Source: US Top News and Analysis